Actively Recruiting

Phase 3
Age: 18Years - 74Years
All Genders
NCT07144163

A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia

Led by Crinetics Pharmaceuticals Inc. · Updated on 2026-04-30

150

Participants Needed

26

Research Sites

72 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of this study is to evaluate the efficacy, safety, PK, and PD of atumelnant in adults with classic CAH due to 21-OHD.

CONDITIONS

Official Title

A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia

Who Can Participate

Age: 18Years - 74Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Male or female, aged 18 to under 75 years at consent
  • Willing and able to follow study procedures and treatment
  • Confirmed classic CAH due to 21-hydroxylase deficiency
  • Morning serum androstenedione (A4) levels meeting specified criteria with corresponding glucocorticoid doses
  • Stable glucocorticoid replacement regimen with no dose changes >5 mg/day hydrocortisone equivalent within 2 months prior to screening
  • Stable mineralocorticoid dose for at least 1 month prior to screening with normal serum sodium and potassium and no orthostatic hypotension
  • Stable estrogen therapy dose for at least 3 months prior to screening if applicable
Not Eligible

You will not qualify if you...

  • Diagnosis of any CAH form other than classic 21-hydroxylase deficiency
  • History of bilateral adrenalectomy, hypopituitarism, or other chronic glucocorticoid-requiring conditions
  • Significant medical conditions or abnormal lab tests unrelated to CAH as judged by the investigator
  • Mental conditions impairing understanding or compliance
  • History of cancer except treated dermal squamous or basal cell carcinoma or cervical carcinoma in situ
  • Pregnancy, lactation, or unwillingness to use effective contraception if of childbearing potential
  • Known hypersensitivity to atumelnant or its ingredients
  • Increased risk for adrenal insufficiency as judged by the investigator
  • Severe erythrocytosis as judged by the investigator
  • Prior use of atumelnant before screening

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 26 locations

1

Crinetics Study Site

Chicago, Illinois, United States, 60611

Actively Recruiting

2

Crinetics Study Site

Ann Arbor, Michigan, United States, 48109

Actively Recruiting

3

Crinetics Study Site

Rochester, Minnesota, United States, 55905

Actively Recruiting

4

Crinetics Study Site

Buenos Aires, Buenos Aires F.D., Argentina, 1405

Actively Recruiting

5

Crinetics Study Site

Buenos Aires, Buenos Aires F.D., Argentina, C1012AAR

Actively Recruiting

6

Crinetics Study Site

CABA, Buenos Aires F.D., Argentina, C1199ABB

Actively Recruiting

7

Crinetics Study Site

Córdoba, Córdoba Province, Argentina, X5000JRD

Actively Recruiting

8

Crinetics Study Site

Herston, Queensland, Australia, 4029

Actively Recruiting

9

Crinetics Study Site

Woolloongabba, Queensland, Australia, 4102

Actively Recruiting

10

Crinetics Study Site

Adelaide, South Australia, Australia, 5000

Actively Recruiting

11

Crinetics Study Site

Parkville, Victoria, Australia, 3050

Actively Recruiting

12

Crinetics Study Site

Nedlands, Western Australia, Australia, 6009

Actively Recruiting

13

Crinetics Study Site

Curitiba, Paraná, Brazil, 33172

Actively Recruiting

14

Crinetics Study Site

Rio de Janeiro, Rio de Janeiro, Brazil, 20551-030

Actively Recruiting

15

Crinetics Study Site

Botucatu, São Paulo, Brazil, 18618-686

Actively Recruiting

16

Crinetics Study Site

São Paulo, São Paulo, Brazil, 04024-002

Actively Recruiting

17

Crinetics Study Site

São Paulo, São Paulo, Brazil, 05403-000

Actively Recruiting

18

Crinetics Study Site

Angers, France, 49933

Actively Recruiting

19

Crinetics Study Site

Bron, France, 69500

Actively Recruiting

20

Crinetics Study Site

Nantes, France, 44093 Cedex 1

Actively Recruiting

21

Crinetics Study Site

Pessac, France, 33604

Actively Recruiting

22

Crinetics Study Site

Vandœuvre-lès-Nancy, France, 54500

Actively Recruiting

23

Crinetics Study Site

Munich, Bavaria, Germany, 80336

Actively Recruiting

24

Crinetics Study Site

Würzburg, Germany, 97080

Actively Recruiting

25

Crinetics Study Site

Milan, Milano, Italy, 20149

Actively Recruiting

26

Crinetics Study Site

Warsaw, Masovian Voivodeship, Poland, 00-189

Actively Recruiting

Loading map...

Research Team

C

Crinetics Clinical Trials

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here